Nanobodies to cross the blood-brain barrier. KU Leuven
Effective delivery of antibodies across the blood–brain barrier (BBB) is a serious limiting factor in the further development of antibody based therapies for AD but also for other diseases of the central nervous system (CNS). The BBB is composed of a tightly sealed monolayer of brain endothelial cells (BECs), which normally precludes free exchanges of solutes between blood and brain (and vice versa), including biologics, but yet enabling the ...